Zachary Segal, MD
Ophthalmology · South Miami, FLNPI 1881630887
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,676 of the $5,938 with a category attached, or 78.8%. It is spread thinly across 24 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 143 payments — averaging $41.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Eyepoint US, Inc.$1K
- Alcon$924
- NEW World Medical,inc.$760
- Johnson & Johnson Surgical Vision, Inc.$372
- Bausch & Lomb Americas Inc.$267
- plus $966 from 18 others
Across 204 payments — averaging $5393.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$205K
- AbbVie$200K
- Roche TCRC, Inc.$172K
- Novartis$166K
- Regeneron$152K
- Eyepoint US, Inc.$104K
- plus $101K from 7 others
What the payments were for
- Travel & lodging$1,16820%
- Food & beverage$4,67679%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $1,349 |
| Eyepoint US, Inc. | 3 | $1,301 |
| Alcon | 19 | $924 |
| NEW World Medical,inc. | 6 | $760 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $372 |
| Bausch & Lomb Americas Inc. | 4 | $267 |
| Mallinckrodt Hospital Products Inc. | 13 | $247 |
| Harrow Eye, LLC | 5 | $144 |
| Genentech USA, Inc. | 6 | $107 |
| Biotissue Holdings Inc. | 1 | $58 |
| Ocular Therapeutix, Inc. | 4 | $58 |
| Glaukos Corporation | 2 | $52 |
| Sight Sciences, Inc. | 1 | $51 |
| Sun Pharmaceutical Industries Inc. | 2 | $36 |
| Astellas Pharma US Inc | 1 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Eyevance Pharmaceuticals LLC | 1 | $26 |
| Dompe US, Inc. | 1 | $25 |
| Ivantis, Inc | 1 | $23 |
| Novartis | 1 | $21 |
| Alimera Sciences, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$1,289
- Kahook Dual Blade$660
- Clearpath$660
- Ahmed Glaucoma Valve$660
- Streamline$660
- Tecnis IOL$535
- Via360$419
- Clareon$303
- DURYSTA$243
- Hydrus Microstent$139
- STELLARIS$135
- TORIC$135
How this compares
$5,938 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 435 | $1,159,506 |
| RestasisCyclosporine | 545 | $476,148 |
| LumiganBimatoprost | 813 | $302,560 |
| DurystaBimatoprost | 67 | $259,186 |
| CombiganBrimonidine Tartrate/Timolol | 421 | $113,987 |
| Prednisolone Acetate | 2,437 | $68,537 |
| XiidraLifitegrast | 62 | $61,965 |
| IzervayAvacincaptad Pegol Sodium/Pf | 13 | $41,125 |
| Alphagan PBrimonidine Tartrate | 141 | $34,303 |
| Cyclosporine | 78 | $26,885 |
| MieboPerfluorohexyloctane/Pf | 28 | $25,209 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 292 | $25,130 |
| VyzultaLatanoprostene Bunod | 67 | $24,919 |
| CequaCyclosporine | 38 | $23,556 |
| Latanoprost | 2,391 | $22,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Durysta, Combigan, Alphagan P | $1,349 | $1,203,7172,015 claims |
| Regeneron Healthcare Solutions, Inc.Eylea | $15 | $1,159,506435 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $267 | $112,093157 claims |
| Astellas Pharma US IncIzervay | $32 | $41,12513 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $36 | $23,55638 claims |
| AlconSimbrinza | $924 | $15,23367 claims |
| NovartisIlevro | $21 | $9,29925 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $26 | $3,76116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in South Miami
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.